Mood and mental health during GLP-1 treatment in Miami
FDA's review found no increased risk of suicidal thoughts or behavior with GLP-1 medicines. New or worsening mood symptoms still deserve attention. Learn what that finding means, how to involve existing care, and where to get crisis support.
Current evidence on GLP-1 medicines and mental health
In January 2026, FDA reported that its comprehensive review did not identify an increased risk of suicidal thoughts or behavior with GLP-1 medicines. It requested removal of that warning from Saxenda, Wegovy medication and Zepbound medication labeling. This is more specific than saying a review is still underway. It also does not mean that a person taking one of these medicines cannot experience a mental-health crisis.
A population-level finding cannot explain an individual's new symptoms. Tell a healthcare professional about new or worsening depression, unusual behavior or suicidal thoughts. Note when a change began and how it affects sleep, relationships or daily responsibilities. Information about weight loss medications can identify the product being discussed, but it cannot determine what caused a mood change or replace a mental-health assessment.
Existing psychiatric care and all current medicines belong in a weight loss eligibility assessment. Describe the support you already receive and any recent changes, without assuming that one diagnosis automatically settles the prescribing decision. The clinician needs the individual history and proposed medicine. If distress is immediate, seek crisis support now rather than waiting to establish whether treatment contributed to it.
Straight answer
What to do
Handling mood changes during treatment
Say so at the start
If you live with depression or anxiety, that belongs in the history. It changes what gets monitored, not whether you are treated.
Raise changes early
A shift in mood, motivation or sleep is worth mentioning at the next review rather than waiting to see whether it passes.
Check the obvious things
Very low intake, dehydration and poor sleep all affect mood independently, and all are common in the first weeks.
Escalate when needed
Thoughts of self-harm are not something to raise at a scheduled review. Contact a clinician or an urgent service the same day.
The wider picture
Mental health support alongside changes in weight treatment
Weight management and mental-health care can involve different professionals with different responsibilities. In physician-supervised weight loss, ask who handles medication concerns and how relevant information can be shared with your existing mental-health clinician. Continue that relationship rather than assuming a weight-management appointment includes psychiatric treatment. A personalized weight loss plan can include practical preferences about appointments, privacy and goals. Explain when weight-focused conversations or changes in routine are distressing so those concerns can be addressed without reducing the discussion to a number on the scale.
Changes in sleep, eating or energy deserve an individual assessment. They should not automatically be blamed on the prescription, a lack of willpower or eating too little. Questions about nutrition during GLP-1 treatment can be raised alongside mental-health concerns, while a review of GLP-1 drug interactions keeps other medicines in view. Bring a brief account of what changed and when, including any recently started or stopped treatment. Do not alter a psychiatric prescription on the assumption that a weight-loss medicine will replace its benefit.
Eating and social routineChanges
How others respondChanges
Both of themWorth raising
Side effects
Other side effect topics
The common list, nausea, red flags and interactions.
Questions about emotional wellbeing during medical weight management
Research findings, ongoing mental-health care and immediate support serve different needs.
The weight-management products discussed here are not FDA-approved depression treatments. Findings about their psychiatric safety do not establish an antidepressant benefit. If you are considering semaglutide medication, keep the reason for that prescription separate from your mental-health treatment and ask the relevant clinician about each.
Describe both, including their timing, changes in sleep or daily functioning, and any treatment changes. A record of common GLP-1 symptoms can add context, but it cannot show that a physical symptom explains depression. Contact a healthcare professional about new or worsening mood symptoms rather than waiting for a symptom diary to establish a cause.
Do not stop or change it on that assumption. Tell both prescribing professionals about the complete treatment plan and ask them to review any proposed change. GLP-1 treatment does not replace an antidepressant or other psychiatric care, and an interaction question needs advice for the exact medicines involved.
No. The free weight loss inquiry is an information contact, not a psychiatric evaluation or crisis service. A licensed healthcare professional must assess symptoms and treatment needs. Avoid sending detailed psychiatric records through a general inquiry form.
In the United States, call or text 988 for immediate suicide and emotional-crisis support. If there is immediate danger or a life-threatening medical emergency, call 911. Do not wait for a weight-management appointment or a response from this website. A medication-safety discussion can follow once immediate support is in place.
It belongs in your history at the start and at any review afterwards. If you are struggling now, speak to a clinician or an urgent service today rather than waiting.
